The ASSAIL-MI trial: a Norwegian multicentre, randomised controlled trial designed to assess the effect of tocilizumab on ischaemia reperfusion injury in ST-elevation myocardial infarction
Event:
Heart Failure 2018
Topic:
Revascularisation
Session:
Coronary Artery Disease – Treatment
